To Investigate Olfactory Impairment in Cerebellar Ataxia

Mariana Moscovich,Renato Munhoz,Helio Teive,Salmo Raskin,Jilin Liu,Karen Mcfarland,Tetsuo Ashizawa,Andrew Lees,Laura Silveira-Moriyama
DOI: https://doi.org/10.1212/wnl.78.1_meetingabstracts.p05.015
IF: 9.9
2012-01-01
Neurology
Abstract:Objective: To investigate olfactory impairment in cerebellar ataxia. Background The main clinical manifestations of spinocerebellar ataxia (SCA) result from the involvement of the cerebellum and its connections feature. Cerebellar activity has been consistently observed in functional imaging studies of olfaction, but the anatomical pathways responsible for this connection have not yet been elucidated. Previous studies have demonstrated olfactory deficit in SCA2, Friedreich9s ataxia and in small groups of ataxia of diverse etiology. Design/Methods: A previously validated translation of the 16 item smell identification test from Sniffin9 Sticks (SS-16) was used to evaluate the sense of smell in 36 autosomal dominant ataxia (ADCA), 31 unknown ataxia patients and compared with groups of 106 Parkinson9s disease (PD) patients and 218 healthy controls. Results: All 392 subjects demonstrated that the SS-16 score was significantly lower in ataxia than in the control group (p Conclusions: Odor identification in ataxia patients is diminished but not to the same extent as in idiopathic PD and further studies are warranted to confirm the presence of hyposmia in pure cerebellar ataxia. Disclosure: Dr. Moscovich has nothing to disclose. Dr. Munhoz has nothing to disclose. Dr. Teive has nothing to disclose. Dr. Raskin has nothing to disclose. Dr. Liu has nothing to disclose. Dr. McFarland has nothing to disclose. Dr. Ashizawa has nothing to disclose. Dr. Lees has received personal compensation for activities with Genus, Novartis, Teva, Meda, Boehringer Ingelheim, GlaxoSmithKline, Ipsen, Lundbeck, Allergan, Orion, BIAL, Noscira and Roche. Dr. Lees has received research support from the PSP Association and Weston Trust - The Reta Lila Howard Foundation. Dr. Silveira-Moriyama has nothing to disclose.
What problem does this paper attempt to address?